News articles about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptose Biosciences earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0579336368058 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Aptose Biosciences Inc. (APTO) Expected to Post Earnings of -$0.22 Per Share (americanbankingnews.com)
- Aptose Now In ‘Hurry Up And Wait’ Mode (seekingalpha.com)
- Aptose Biosciences (APTO) Announces Earnings Results (americanbankingnews.com)
- Aptose Biosciences’ (APTO) “Buy” Rating Reaffirmed at HC Wainwright (americanbankingnews.com)
- Aptose Biosciences: 2Q Earnings Snapshot (finance.yahoo.com)
Shares of APTO stock traded down $0.03 during trading on Friday, hitting $3.02. 168,649 shares of the stock traded hands, compared to its average volume of 267,487. The firm has a market cap of $101.91 million, a PE ratio of -5.81 and a beta of 2.40. Aptose Biosciences has a 52-week low of $1.30 and a 52-week high of $4.55.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.10). sell-side analysts forecast that Aptose Biosciences will post -0.89 EPS for the current fiscal year.
A number of research analysts have weighed in on the stock. ValuEngine raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. HC Wainwright reissued a “buy” rating and issued a $8.50 target price on shares of Aptose Biosciences in a research note on Friday, June 29th. Roth Capital set a $6.00 target price on shares of Aptose Biosciences and gave the stock a “buy” rating in a research note on Monday, April 16th. Finally, Zacks Investment Research lowered shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, April 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Aptose Biosciences presently has a consensus rating of “Hold” and an average price target of $6.38.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.